2019
Risk Factors for Kidney Disease in Type 1 Diabetes
Perkins BA, Bebu I, de Boer IH, Molitch M, Tamborlane W, Lorenzi G, Herman W, White NH, Pop-Busui R, Paterson AD, Orchard T, Cowie C, Lachin JM, Group O. Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care 2019, 42: dc182062. PMID: 30833370, PMCID: PMC6489116, DOI: 10.2337/dc18-2062.Peer-Reviewed Original ResearchConceptsHigher systolic blood pressureHigher mean triglyceridesSystolic blood pressureRisk factorsKidney diseaseBlood pressureIncident macroalbuminuriaMean triglyceridesMultivariable Cox proportional hazards modelsGlomerular filtration rate lossCox proportional hazards modelComplications Trial (DCCT) cohortNonglycemic risk factorsModifiable risk factorsFrequency of screeningAssociation of baselineType 1 diabetesProportional hazards modelGlycemic exposureTrial cohortDiabetes controlMale sexHazards modelClinical strategiesAdvanced stage
2016
Barriers to participation in industry‐sponsored clinical trials in pediatric type 2 diabetes
Farrell R, Bethin K, Klingensmith G, Tamborlane WV, Gubitosi‐Klug R. Barriers to participation in industry‐sponsored clinical trials in pediatric type 2 diabetes. Pediatric Diabetes 2016, 18: 574-578. PMID: 27807915, DOI: 10.1111/pedi.12465.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAttitude of Health PersonnelChildDiabetes Mellitus, Type 2Drug ApprovalDrug IndustryDrugs, InvestigationalEndocrinologyHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInternetNeeds AssessmentPatient SelectionPediatricsRandomized Controlled Trials as TopicResearch PersonnelResearch Support as TopicSocieties, ScientificSurveys and QuestionnairesUnited StatesUnited States Food and Drug AdministrationWorkforceConceptsPediatric Endocrine SocietyType 2 diabetesClinical trialsPediatric endocrinologistsIndustry-sponsored clinical trialsPatients age 18 yearsPediatric type 2 diabetesCurrent glycemic controlNew T2D casesAdditional treatment optionsAge 18 yearsBaseline demographicsT2D patientsGlycemic controlMedication useMultiple medicationsPediatric patientsResearch nursesPediatric populationTreatment optionsEndocrine SocietyT2D casesDrug AdministrationVisit scheduleAnonymous online survey
2014
The Artificial Pancreas: Are We There Yet?
Cefalu WT, Tamborlane WV. The Artificial Pancreas: Are We There Yet? Diabetes Care 2014, 37: 1182-1183. PMID: 24757224, PMCID: PMC5131852, DOI: 10.2337/dc14-0491.Peer-Reviewed Original ResearchDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansInsulin Infusion SystemsInsulin ResistancePancreas, ArtificialRandomized Controlled Trials as Topic
2013
Extended 6-Month Follow-Up of A Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children Aged 4 to <10 Years
Tansey M, Weinzimer S, Beck R, Ruedy K, Cheng P, Tamborlane W, Kollman C, Mauras N, Fox L, Coffey J, White NH, Group F. Extended 6-Month Follow-Up of A Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children Aged 4 to <10 Years. Diabetes Care 2013, 36: e63-e63. PMID: 23613604, PMCID: PMC3631880, DOI: 10.2337/dc12-2021.Peer-Reviewed Original ResearchMeSH KeywordsBlood Glucose Self-MonitoringChildChild, PreschoolDiabetes Mellitus, Type 1FemaleFollow-Up StudiesGlycated HemoglobinHumansHypoglycemic AgentsInsulinMaleRandomized Controlled Trials as Topic
2012
The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence
Ruedy KJ, Tamborlane WV, for the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence. Journal Of Cardiovascular Translational Research 2012, 5: 380-387. PMID: 22538483, DOI: 10.1007/s12265-012-9364-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkersBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1Equipment DesignEvidence-Based MedicineGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsMulticenter Studies as TopicPatient SatisfactionPredictive Value of TestsRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsContinuous glucose monitorRandomized trialsT1D managementMulticenter Randomized TrialType 1 diabetesStandard glucose monitoringPrimary studiesComplications TrialSevere hypoglycemiaHemoglobin levelsDiabetes controlBiochemical hypoglycemiaCGM usePatientsGlucose monitoringAccumulated evidenceSecondary studiesReduced exposureTrialsA1CHypoglycemiaGlucose monitorSubjectsDCCTDiabetesUse of continuous glucose monitoring in children and adolescents *
Phillip M, Danne T, Shalitin S, Buckingham B, Laffel L, Tamborlane W, Battelino T, Participants F. Use of continuous glucose monitoring in children and adolescents *. Pediatric Diabetes 2012, 13: 215-228. PMID: 22284160, DOI: 10.1111/j.1399-5448.2011.00849.x.Peer-Reviewed Original Research
2010
Effect of Prior Intensive Therapy in Type 1 Diabetes on 10-Year Progression of Retinopathy in the DCCT/EDIC: Comparison of Adults and Adolescents
White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, Davis MD, . Effect of Prior Intensive Therapy in Type 1 Diabetes on 10-Year Progression of Retinopathy in the DCCT/EDIC: Comparison of Adults and Adolescents. Diabetes 2010, 59: 1244-1253. PMID: 20150283, PMCID: PMC2857905, DOI: 10.2337/db09-1216.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultDiabetes Mellitus, Type 1Diabetic RetinopathyDisease ProgressionFemaleFollow-Up StudiesGlycated HemoglobinHumansMaleRandomized Controlled Trials as TopicYoung AdultConceptsEDIC year 10Beneficial effectsPrior glycemic controlPrior intensive therapyProgression of retinopathyDCCT/EDICYear 10Type 1 diabetesComplications StudyDCCT closeoutMean A1CComplications TrialA1c levelsGlycemic controlIntensive therapySevere hypoglycemiaDiabetes controlINT groupDiabetes InterventionsDiabetic retinopathyCON groupSlow progressionConventional groupFormer adolescentsComparison of adult
2006
The renaissance of insulin pump treatment in childhood type 1 diabetes
Tamborlane WV, Swan K, Sikes KA, Steffen AT, Weinzimer SA. The renaissance of insulin pump treatment in childhood type 1 diabetes. Reviews In Endocrine And Metabolic Disorders 2006, 7: 205-213. PMID: 17160722, DOI: 10.1007/s11154-006-9018-9.Peer-Reviewed Original ResearchMeSH KeywordsChildClinical Trials as TopicDiabetes Mellitus, Type 1Glycated HemoglobinHumansInfusion Pumps, ImplantableInsulin Infusion SystemsPatient SelectionPsychologyRandomized Controlled Trials as TopicRisk AssessmentTreatment OutcomeConceptsContinuous subcutaneous insulin infusionQuality of lifePump therapyEfficacy of CSIINormal blood sugar levelsType 1 diabetes mellitusChildhood type 1 diabetesRisk of hypoglycemiaInsulin pump therapyBlood sugar levelsSubcutaneous insulin infusionType 1 diabetesNew insulin analoguesTreatment of childrenMacrovascular complicationsDiabetes mellitusPediatric patientsSevere hypoglycemiaHemoglobin levelsPatient selectionTreatment optionsInsulin infusionClinical studiesAge of childrenInsulin analogues
2005
Insulin Pump Treatment of Childhood Type 1 Diabetes
Weinzimer SA, Sikes KA, Steffen AT, Tamborlane WV. Insulin Pump Treatment of Childhood Type 1 Diabetes. Pediatric Clinics Of North America 2005, 52: 1677-1688. PMID: 16301088, DOI: 10.1016/j.pcl.2005.07.004.Peer-Reviewed Original ResearchMeSH KeywordsBlood GlucoseBlood Glucose Self-MonitoringChildClinical Trials as TopicDiabetes Mellitus, Type 1HumansInsulinInsulin Infusion SystemsRandomized Controlled Trials as TopicTreatment OutcomeConceptsContinuous subcutaneous insulin infusionQuality of lifeLong-term microvascular complicationsEfficacy of CSIINormal blood sugar levelsType 1 diabetes mellitusInsulin pump treatmentChildhood Type 1Risk of hypoglycemiaBlood sugar levelsSubcutaneous insulin infusionNew insulin analoguesTreatment of childrenMicrovascular complicationsDiabetes mellitusPump treatmentSevere hypoglycemiaHemoglobin levelsTreatment optionsInsulin infusionClinical studiesAge of childrenInsulin analoguesType 1Weight gain